• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Comparable outcomes amongst three different types of drug-eluting stents in BIO-RESORT Trial

byDavy LauandAlex Chan
November 15, 2022
in Cardiology, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. At 5 years follow-up, rates of target vessel failure were comparable amongst 3 types of drug-eluting stents (DES), in all-comers and patients with diabetes, including Orsiro sirolimus (SES), Synergy everolimus (EES), and Resolute Integrity zotarolimus (ZES),.

Evidence Rating Level: 1 (Excellent)

There are numerous drug-eluting stents (DES) used to prevent vessel failure after percutaneous coronary intervention (PCI), including Orsiro sirolimus (SES), Synergy everolimus (EES), and Resolute Integrity zotarolimus (ZES) eluting stents. The BIO-RESORT randomized trial based in the Netherlands aimed to compare these 3 DES, and found no difference in safety and efficacy at 1 year amongst all-comers. Currently at 5-years follow-up, this study compared the efficacy of each DES amongst all-comers and amongst patients with diabetes. The efficacy was measured in terms of target vessel failure (TVF) occurrence, including myocardial infarction, revascularization, or cardiac mortality. In total, 3514 all-comers were randomized 1:1:1 to the 3 DES, with 3183 (90.6%) available at 5-year follow-up. The mean (SD) age was 63.9 (10.8) years, with 72.5% male. The study found no significant differences in TVF amongst all-comers, which occurred in 12.7% of SES patients, 11.6% of EES patients, and 14.1% of ZES patients (SES vs ZES: Hazards ratio 0.89, 95% CI 0.71-1.12, p = 0.31; EES vs ZES: HR 0.82, 95% CI 0.65-1.04, p = 0.10). As well, there was no significant difference in incidence of stent thrombosis. Amongst patients with diabetes, there were no significant differences in TVF, which occurred in 19.8% of SES patients, 19.2% of EES patients, and 21.1% of ZES patients (SES vs ZES: HR 0.91, 95% CI 0.59-1.42, p = 0.69; EES vs ZES: HR 0.90, 95% CI 0.58-1.40, p = 0.63). Overall, this study showed comparable efficacy outcomes amongst 3 DES types, in both all-comers and patients with diabetes.

Click to read the study in JAHA

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Clopidogrel monotherapy is superior to aspirin for secondary prevention in coronary artery disease

Influenza vaccination improves survival and reduces readmissions in patients hospitalized for acute heart failure

Multidomain rehabilitation after myocardial infarction improves outcomes in older adults

Tags: cardiologythrombosis
Previous Post

Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

Next Post

#VisualAbstract: Renal artery denervation is effective and well-tolerated for blood pressure reduction

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Clopidogrel monotherapy is superior to aspirin for secondary prevention in coronary artery disease

October 30, 2025
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Cardiology

Influenza vaccination improves survival and reduces readmissions in patients hospitalized for acute heart failure

October 29, 2025
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Multidomain rehabilitation after myocardial infarction improves outcomes in older adults

October 15, 2025
Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)
Cardiology

Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy

October 14, 2025
Next Post
#VisualAbstract: Renal artery denervation is effective and well-tolerated for blood pressure reduction

#VisualAbstract: Renal artery denervation is effective and well-tolerated for blood pressure reduction

Combined immunotherapy may improve survival in metastatic pancreatic cancer

Triple mRNA vaccination and previous COVID-19 exposure provide protection against the omicron variant

Moderna mRNA COVID-19 vaccine is safe in children six months to five years of age

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial
  • One dose of human papillomavirus vaccine noninferior to two for preventing persistent infection
  • Combined Gastric Electrical Stimulation and Pyloroplasty in Gastroparesis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.